Private Trust Co. NA Acquires 27 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Private Trust Co. NA lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 191 shares of the biopharmaceutical company’s stock after acquiring an additional 27 shares during the period. Private Trust Co. NA’s holdings in Regeneron Pharmaceuticals were worth $100,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Nuveen LLC bought a new position in Regeneron Pharmaceuticals during the first quarter worth about $343,764,000. Pacer Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock worth $258,366,000 after buying an additional 390,374 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock worth $724,984,000 after buying an additional 174,056 shares during the period. Vanguard Group Inc. lifted its position in shares of Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock worth $5,966,767,000 after buying an additional 121,545 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Regeneron Pharmaceuticals by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after buying an additional 89,579 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN opened at $584.74 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The stock has a market capitalization of $61.98 billion, a P/E ratio of 14.74, a price-to-earnings-growth ratio of 1.81 and a beta of 0.31. The company’s 50 day simple moving average is $576.17 and its 200-day simple moving average is $562.42. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $959.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $11.56 EPS. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REGN. Citigroup lifted their price objective on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a report on Monday, October 13th. Jefferies Financial Group increased their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research report on Wednesday, August 27th. Sanford C. Bernstein boosted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a “buy” rating and a $890.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $817.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.